Bristol Myers Squibb Announces FDA Accelerated Approval of KRAZATI® for KRAS G12C-Mutated Colorectal Cancer
Today, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI® (adagrasib) in combination with cetuximab. This targeted treatment is for adult…
EMA Validates Bristol Myers Squibb’s Subcutaneous Nivolumab Application
Bristol Myers Squibb announced today that the European Medicines Agency (EMA) has validated its application to introduce a new subcutaneous administration route for Opdivo® (nivolumab). This includes a new pharmaceutical…
Audrey Duval Derveloy Named Global Head of Corporate Affairs, Joins Sanofi Executive Committee
Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed…
Lilly’s Tirzepatide Reduces OSA Severity, Resolves Disease in 51.5% of Participants
Eli Lilly and Company (NYSE: LLY) has released detailed results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated tirzepatide injections (10 mg or 15 mg) for treating moderate-to-severe obstructive…
Sanofi and Biovac Enhance Polio Vaccine Manufacturing in Africa
Sanofi and Biovac, based in Cape Town, South Africa, have announced a significant partnership aimed at local manufacturing of inactivated polio vaccines (IPV) across Africa. This collaboration marks a milestone…
EU Approves Truqap Plus Faslodex for Advanced ER-Positive Breast Cancer Treatment
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast…
Roche Unveils Advanced Test for Easier B-Cell Lymphoma Diagnosis
Roche announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the…
FDA Approves SKYRIZI® for Ulcerative Colitis, Expanding AbbVie’s IBD Portfolio
FDA Approves SKYRIZI® for Ulcerative Colitis, Expanding AbbVie’s IBD Portfolio AbbVie announced that the U.S. FDA has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis. This…
Eli Lilly’s Open Letter on Mounjaro® and Zepbound® Practices
Lilly’s Commitment to Safe Use of Mounjaro® and Zepbound® Lilly is dedicated to improving lives for people with diabetes and obesity through innovative medications like Mounjaro® and Zepbound®. Guided by…
Actylis Announces Appointment of Scott Thomson as Chief Executive Officer
Actylis, a prominent global manufacturer and sourcing expert specializing in critical materials and performance ingredients for life sciences and specialty chemicals, has appointed Scott Thomson as its new Chief Executive…
Marinus Pharmaceuticals Releases Key Findings from IV Ganaxolone Phase 3 RAISE Trial for Refractory Status Epilepticus
Marinus Pharmaceuticals, a company focused on developing innovative therapeutics for seizure disorders, has announced topline results from the Phase 3 RAISE trial (NCT04391569). This double-blind, randomized, placebo-controlled study assessed the…
Takeda Reports Phase 3 Findings of Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
Takeda Releases Phase 3 Topline Results for Soticlestat (TAK-935) in Dravet Syndrome and Lennox-Gastaut Syndrome OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE The SKYLINE trial (TAK-935-3001) was a multicenter, randomized,…